Status: Recruiting
DESTINY-PANTUMOUR04
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US
Participants needed: 100
Trial details
Age: 18-130Biological sex: AllType: ObservationalSponsor: AstraZenecaUpdated: Jun 29, 2026Locations: 17
Eligibility criteria
Adults aged ≥18 years [+4]
Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon o... [+3]